Definium Therapeutics (NASDAQ:DFTX) Given New $50.00 Price Target at Needham & Company LLC

Definium Therapeutics (NASDAQ:DFTX) had its price target upped by equities researchers at Needham & Company LLC from $38.00 to $50.00 in a report released on Tuesday. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 36.35% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright boosted their target price on Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday. Piper Sandler reissued an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Stifel Nicolaus set a $30.00 price objective on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday, April 16th. Finally, Citigroup restated a “buy” rating on shares of Definium Therapeutics in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $44.54.

Definium Therapeutics Stock Up 49.8%

Definium Therapeutics stock opened at $36.67 on Tuesday. Definium Therapeutics has a 1-year low of $6.34 and a 1-year high of $39.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The stock has a market cap of $3.66 billion, a PE ratio of -14.73 and a beta of 2.37. The stock’s fifty day moving average is $22.98 and its two-hundred day moving average is $18.58.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, sell-side analysts expect that Definium Therapeutics will post -2.3 EPS for the current fiscal year.

Institutional Trading of Definium Therapeutics

A number of large investors have recently made changes to their positions in the company. Commodore Capital LP grew its stake in Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after buying an additional 475,000 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in Definium Therapeutics in the third quarter valued at approximately $4,337,000. Rosalind Advisors Inc. lifted its stake in Definium Therapeutics by 78.6% in the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after buying an additional 330,000 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Definium Therapeutics by 424.9% in the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after acquiring an additional 239,965 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Definium Therapeutics by 11.0% in the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after acquiring an additional 198,878 shares during the period. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Phase 3 Emerge data for DT120 were positive, with the study meeting the primary endpoint and all key secondary efficacy endpoints in major depressive disorder. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
• Positive Sentiment: Investors are also reacting to reports that the drug showed “best-case” late-stage results, suggesting meaningful commercial potential if the data hold up in full analysis and regulatory discussions. Definium’s LSD-based pill reduces depression symptoms in late-stage trial
• Neutral Sentiment: The company said it will host a webcast to discuss the results, which could provide more detail on efficacy, safety, and next steps for DT120. Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: Definium also announced a proposed $500 million public offering, which could dilute existing shareholders even as the stock benefits from the trial win. Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.